Balancing Medical Discovery and Respect for Patients, with Henrietta Lacks in Mind

Tissue and blood samples taken from patients can hold the keys to biomedical discovery. But the research community must consider patient privacy, a new perspective says.

1:00 PM

Author | Kara Gavin

When Henrietta Lacks died six decades ago, she didn't know her cancer cells would live on and help scientists make thousands of medical discoveries affecting the lives of millions of people. They even led to a vaccine that can prevent the cervical cancer that killed her.

Controversially, as the best-selling book The Immortal Life of Henrietta Lacks documented, the cells were used without her knowledge or permission, her identity barely disguised.

This week, an HBO movie tells her story, with Oprah Winfrey starring as Lacks' daughter. As the movie airs, researchers are still trying to balance the great benefits of scientific discovery with the privacy rights of the people whose tissue or blood the research depends on.

A new paper by University of Michigan researchers looks at how that balance stands — and how it will change in January if new rules are put in place. The perspective is published in the Journal of Clinical Oncology.

U-M medical student Joshua D. Smith, senior author and head and neck surgeon and clinical ethicist Andrew Shuman, M.D., and co-author Kayte Spector-Bagdady, J.D., M.B.E., focused their work on what the new rules mean for cancer research, using the process at U-M for head and neck tumor patients as an example. But the summary applies to just about any kind of research that studies cells, genes, proteins and other tiny parts of the human machinery that play a role in disease.

The 'Common Rule' for research samples

Researchers today follow a much stricter standard than what was in place in Henrietta Lacks' day, requiring them to get a patient's informed consent before taking identifiable samples to use in research.

Once researchers have consent, they can use those samples, so long as they protect the patient's privacy.

Under these guidelines, the U-M head and neck cancer team has even harnessed some "immortal" cancer cells from its past patients to create cell lines that it has shared with researchers across the world.

The new Common Rule, which is slated to take effect in January, will better guide researchers in obtaining and using research specimens, says Smith.

It will also allow researchers to ask patients for permission to give "broad consent" — which allows an authorized researcher with institutional review board approval to use their samples with their information attached, as long as the researchers protect their privacy.

"If a patient consents to donate tissue today, there should be some information provided about what it will be used for, but ideally researchers should also share that we don't know what type of information we'll be able to generate from that same sample years from now," Smith says.

Unlike Lacks, today's patients can say no and decline to let identifiable samples taken from them be used for research. If they say yes, they're also generally advised that they can't expect any financial gain if, say, their sample is used to discover a new drug that a pharmaceutical company goes on to sell.

But the Common Rule revision stopped short of requiring that researchers go back to the patients who donated samples years ago and get consent.

Thankfully, Smith says, the final Common Rule also doesn't include a controversial provision that would have made researchers stop using samples 10 years after they were obtained.

If those provisions had been included, it could have stopped research using cell lines or archived samples dead in its tracks. But it does require research institutions and federal agencies to revisit their standards at least every four years in light of new technological breakthroughs and societal shifts.

For example, whole-genome sequencing can generate information that might not have a name or medical record associated with it, but it is still unique to one person. In the future, regulators may decide that technologies such as whole-genome sequencing should not be applied to specimens without consent because of the risk of being able to identify the participants.

Ensuring that standards for using patient samples are revisited often is a key provision of the new rule, says Smith — especially given how quickly scientific tools are improving.

A call for further updates

Despite progress, bioethics research on how patients understand the informed consent documents and information about how their samples might be used still needs to improve, says Spector-Bagdady.

Smith notes that as a physician-in-training, he sees time as a major issue. The speed of modern clinic visits means there might be pressure to rush through the informed consent process, rather than making sure the patient reads and understands it before signing.

"Many of the changes to the Common Rule won't be visible to patients, but rather will be behind the scenes, with the researchers and the institutions that oversee research," he says. "All of us need to make sure our practices keep up with the times and evaluate what we're doing to ensure privacy and confidentiality while not getting in the way of science."

But as Lacks' story again hits the public eye, Smith says, it's important to remember "how many scientific breakthroughs have come from her cell line. It was her gift to science, whether that was her choice or not."

He adds, "Without her, we would not be anywhere close to where we are in cancer treatment. And when we're approaching today's patients for consent, we need to say that we don't know exactly what will come from your samples, but that you have the potential to help patients down the road and that we will take your privacy seriously."


More Articles About: Lab Report Cancer Research Drug Discovery Health Care Delivery, Policy and Economics Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Pill capsule pushing through a paper with amoxicillin printed on it.
Health Lab
Rise seen in use of antibiotics for conditions they can’t treat – including COVID-19
Overuse of antibiotics can lead bacteria to evolve antimicrobial resistance, but Americans are still receiving the drugs for many conditions that they can’t treat.
Illustration of hand holding list, with pill bottle in opposite and and small pic of doctor talking to patient
Health Lab
New urine-based test detects high grade prostate cancer, helping men avoid unnecessary biopsies
A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
marijuana leaf drawing blue lab note yellow badge upper left corner
Health Lab
Data shows medical marijuana use decreased in states where recreational use became legal 
Data on medical cannabis use found that enrollment in medical cannabis programs increased overall between 2016 and 2022, but enrollment in states where nonmedical use of cannabis became legal saw a decrease in enrollment
Illustration of prescription bottle with a refill notice
Health Lab
In drive to deprescribe, heartburn drug study teaches key lessons
An effort to reduce use of PPI heartburn drugs in veterans because of overuse, cost and potential risks succeeded, but provides lessons about deprescribing efforts.
Exterior photograph of an urgent care clinic
Health Lab
Thinking outside the doctor’s office: How older adults use urgent care & in-store clinics
In the past two years, 60% of people age 50 to 80 have visited an urgent care clinic, or a clinic based in a retail store, workplace or vehicle, according to new findings from the University of Michigan National Poll on Healthy Aging.
Illustration of hand holding a smartphone with green background
Health Lab
Medicare pays for message-based e-visits. Are older adults using them?
Telehealth study of patient portal e-visits by Medicare participants shows few had an interaction for which their provider billed them.